Saturna Capital Corp Editas Medicine, Inc. Transaction History

Saturna Capital Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$14.08 - $27.63 $234,080 - $459,348	-16,625 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$26.55 - $40.57 $3,318 - $5,071	125 Added 0.76%	16,625 $441,000
Q2 2021 Aug 11, 2021	BUY	$31.29 - $56.64 $179,917 - $325,680	5,750 Added 53.49%	16,500 $935,000
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $25,811 - $58,877	650 Added 6.44%	10,750 $452,000
Q4 2020 Feb 12, 2021	SELL	$27.07 - $84.35 $2,707 - $8,435	-100 Reduced 0.98%	10,100 $708,000
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $1,850 - $3,434	100 Added 0.99%	10,200 $302,000
Q1 2020 May 14, 2020	BUY	$14.88 - $32.78 $47,616 - $104,896	3,200 Added 46.38%	10,100 $200,000
Q4 2019 Feb 13, 2020	BUY	$19.49 - $32.63 $134,481 - $225,147	6,900 New	6,900 $204,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Saturna Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Saturna Capital Corp with notifications on news.